KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Share-based Compensation (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Share-based Compensation data on record, last reported at $43.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 19.84% year-over-year to $43.3 million; the TTM value through Dec 2025 reached $133.9 million, up 2.82%, while the annual FY2025 figure was $133.9 million, 2.82% up from the prior year.
  • Share-based Compensation reached $43.3 million in Q4 2025 per IONS's latest filing, up from $31.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $43.3 million in Q4 2025 and bottomed at $22.3 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $29.5 million, with a median of $29.7 million recorded in 2025.
  • Peak YoY movement for Share-based Compensation: tumbled 76.58% in 2021, then soared 37.26% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $22.3 million in 2021, then rose by 15.41% to $25.7 million in 2022, then grew by 2.52% to $26.3 million in 2023, then soared by 37.26% to $36.1 million in 2024, then increased by 19.84% to $43.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $43.3 million in Q4 2025, $31.1 million in Q3 2025, and $29.7 million in Q2 2025.